Passage Bio IncNASDAQ PASG Stock Report

Passage Bio, Inc. operates as a genetic medicines company. The company is headquartered in Philadelphia, Pennsylvania and currently employs 85 full-time employees. The company went IPO on 2020-02-28. The firm is focused on developing transformative therapies for central nervous system (CNS) disorders. Its first product candidate, PBGM01, utilizes a AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal beta-galactosidase (ß-gal), for GM1. Its second product candidate, PBFT02, utilizes an AAV1 capsid to deliver to the brain a functional GRN gene encoding progranulin (PGRN), for FTD caused by progranulin deficiency (FTD-GRN). Its third product candidate, PBKR03, utilizes a next-generation AAVhu68 capsid to deliver to the brain and peripheral tissues a functional gene encoding the hydrolytic enzyme galactosyl ceramidase, (GALC) for Krabbe disease. The firm also has six programs in the research stage: PBML04 for metachromatic leukodystrophy; PBAL05 for amyotrophic lateral sclerosis; PBCM06 for Charcot-Marie-Tooth Type 2A; and programs for Canavan disease, and others.